Drug class profile · refreshed daily from federal data

Topoisomerase Inhibitor

3 molecules in this class, $780820 combined CY2024 Part D spend across 3K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Topoisomerase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $780820combined across class
Total Rx claims: 3K871 unique beneficiaries
Generic mfrs (active): 27across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Irinotecan

Brand: Camptosar · 2K Part D claims (CY24) · 640 beneficiaries · First FDA approval: 1996-06-14

15 generic mfrs Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $715899

Class share

92%

of class CY24 spend

View profile →

Etoposide

Brand: Avopef · 608 Part D claims (CY24) · 208 beneficiaries · First FDA approval: 1996-05-01

5 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $36955

Class share

of class CY24 spend

View profile →

Topotecan

Brand: HYCAMTIN · 64 Part D claims (CY24) · 23 beneficiaries · First FDA approval: 2010-11-30

7 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $27966

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.